Validation of the Prostate Cancer Assay - Beta+Pivotal

NCT02742259 | Withdrawn FDA Device

• 1 other identifier: Celsee CA1001.v1
• Study Type: observational
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The Prostate Cancer Assay performance of Celsee Diagnostics circulating tumor cell (CTC) analysis system will be validated in patients diagnosed with metastatic prostate cancer. It will demonstrate substantial performance equivalency to a CTC Assay predicate device.

Conditions

Metastatic Prostate Cancer, CTC

Outcome Measures

Primary Outcomes (1)

• Confirmation of the clinical utility of the cutoff level for the Prostate Cancer Assay for prognosis of progression free survival (PFS) in comparison to the predicate device, CellSearch CTC Assay

  "CTC negative" means a level of CTCs below the cutoff indicating lower risk for progression (i.e. PFS, and "CTC positive" means a level of CTCs at or above the cutoff indicating higher risk for progression (i.e. shorter PFS).

  9 months

Study Arms (2)

Beta Cutoff

Assay

Device: Blood Draw

Pivotal

Assay

Device: Blood Draw

Interventions

Blood Draw DEVICE

Blood draws only - non-diagnostic, non-treatment

Beta Cutoff; Pivotal

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Males 18 years and above; Metastatic prostate cancer to the bone as documented by positive bone scan imaging

You may qualify if:

• Male aged 18 years and above
• Be willing to sign an informed consent document indicating that the subject understands the purpose of and procedures required for the study and are willing to participate in the study
• Be willing/able to adhere to the prohibitions and restrictions specified in this protocol
• Eastern cooperative group (ECOG) performance status ≤2
• Documented histologically confirmed adenocarcinoma of the prostate
• Metastatic prostate cancer to the bone as documented by positive bone scan imaging
• CRPC patient being considered for systemic therapy or in between lines of therapies (\>= 14 days from prior treatment) for metastatic disease. Patient must have evidence of castrate resistant prostate cancer as evidenced by a confirmed rising PSA (per Prostate Cancer Working Group 2 \[PCWG2\] criteria) and a castrate serum testosterone level (i.e. ≤ 50 mg/dl).

You may not qualify if:

• Subjects actively receiving systemic therapy regimens, or between lines of therapies (\< 14 days from prior treatment)
• Have any condition that, in the opinion of the investigator, would compromise the wellbeing of the subject or the study or prevent the subject from meeting or performing study requirements
• Active infection or other medical condition that would make corticosteroids (i.e. prednisone) use contraindicated
• Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg) Patients with a history of hypertension are allowed provided blood pressure is controlled by antihypertensive treatment
• Severe hepatic impairment (Child-Pugh Class C)
• History of pituitary or adrenal dysfunction (note: the use of daily steroids does not exclude someone from participating in this study)
• Have poorly controlled diabetes (HgB A1C ≥ 8%)
• Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.
• Abnormal bone marrow function (absolute neutrophil count \[ANC\] \< 1500/mm3, platelet count \<100,000/mm3, hemoglobin \<9 g/dL)
• Abnormal liver function (bilirubin \> upper limit of normal \[ULN\]; AST and/or ALT \> 1.5 x ULN concomitant with alkaline phosphatase \> 2.5 x ULN)
• Abnormal kidney function (serum creatinine ≥ 2 x upper limit of normal)
• Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, unstable atrial fibrillation, or New York Heart Association (NYHA) Class III-IV heart disease
• History of ventricular tachyarrhythmia within the past 5 years

Sponsors & Collaborators

• Celsee Diagnostics: lead

Biospecimen

Retention: NONE RETAINED

10 ml blood draws

MeSH Terms

Conditions

Prostatic Neoplasms; Neoplastic Cells, Circulating

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Neoplasm Metastasis; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Yixin Wang, Ph.D.

  Celsee Diagnostics

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 24, 2016
• First Posted: April 19, 2016
• Study Start: May 1, 2016
• Primary Completion: April 1, 2017
• Study Completion: September 1, 2017
• Last Updated: March 26, 2019

Record last verified: 2019-03

Data Sharing

• IPD Sharing: Will not share